Update: Wyeth’s appeal was discontinued.
On April 30, 2021, the Federal Court issued its decision relating to the validity of three patents relating to Pfizer’s PREVNAR 13, a 13-valent pneumococcal polysaccharide protein...more
5/18/2021
/ Anticipation ,
Claim Construction ,
Novelty ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Patent Invalidity ,
Patent Litigation ,
Patent Validity ,
Patents ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Vaccinations